Host defense against intracellular pathogens such as mycobacteria and salmonellae depends on interactions between macrophages, dendritic cells and NK, and T lymphocytes mediated by the Interleukin-12 (IL-12)/Interferon-g (IFN-g) pathway. Mutations in five genes namely IL-12B, IL12B1, IFNGR1, IFNGR2 and STAT1 that are involved in this pathway, have been recognized to cause the syndrome of Mendelian susceptibility to mycobacterial infection (OMIM 209950). 1, 2 Mutations leading to complete IFN-g receptor 1 (IFNgR1) deficiency have been identified in 22 patients from 17 kindreds and result in the most severe phenotype. 3 Hematopoietic stem cell transplantation (HSCT) has been proposed as the only curative treatment for patients with complete IFNgR1 deficiency. 4, 5 The use of a non T-cell depleted transplant from an HLA-identical sibling and fully myeloablative conditioning regimen provide better results. 6 Although optimal control of infection before HSCT is also recommended, we report here the third successful HSCT that led to the prolonged remission of a child with complete IFNgR1 deficiency and active mycobacterial infection.
A 2-year-old boy presented with persistent fever, eczematoid and maculopapular skin lesions, disseminated lymphadenopathies (cervical, inguinal) and hepatosplenomegaly. The child was born of consanguineous parents and his sister (4 years of age) was healthy. An ultrasound examination confirmed the presence of multiple inguinal and cervical lymphadenopathies with absence of collection. The chest X-ray and CT scan revealed disseminated mediastinal lymph nodes. Blood examination displayed inflammatory microcytic anemia (hemoglobin (Hb) ¼ 9.1 g/ dl), hyperleucocytosis (white blood cells (WBC) ¼ 24 380/ mm 3 ) and moderate inflammatory syndrome (C-reactive Protein (CRP) ¼ 2.1 mg/dl). Two positive Mantoux tuberculin skin tests were reported. Skin and inguinal lymph node biopsies suggested the diagnosis of Langerhans histiocytosis with focal infiltration of S100 and CD1a-positive histiocytic cells and virtual absence of well-formed granuloma. However, electron microscopy examination did not show Birbeck granules and Mycobacterium fortuitum was isolated in the lymph node tissue culture. Enzyme-like immunoabsorbent assay (ELISA) revealed increased levels of IFN-g in the plasma of the patient (200 pg/ml) as well as the absence of IL-12 production after stimulation in vitro of whole blood by Bacille Calmette-Gue´rin (BCG) plus IFN-g assessed as previously described (IL-12p70 after 48 h activation ¼ 0 pg/ml). 7, 8 These analyses were normal in the young sister and the mother. Molecular analysis showed that the child was homozygous for a C77F mutation in the exon 3 of IFNGR1 gene that results in complete lack of IFNgR1 expression. 9 Treatment with oral clarithromycin (15 mg/kg/day) and cotrimoxazole (7 mg trimethoprim/kg/ day) was initiated according to the M. fortuitum antibiogram and allowed rapid regression of symptoms (Hb ¼ 10.6 g/dl, WBC ¼ 8340/mm 3 , CRPo0.3 mg/dl). However, 6 months later, the child presented with recurrence of right inguinal and cervical lymphadenopathies, maculopapular rash and biological signs of active infection (Hb ¼ 7.8 mg/dl, WBC ¼ 8190/mm 3 , CRP ¼ 4.6 mg/dl). As his sister was HLA-identical, a bone marrow transplantation was initiated 7 days after starting intravenous antibiotherapy (amikacin 15 mg/kg/day and ciprofloxacin 20 mg/kg/day). Conditioning regimen included busulfan (4 mg/kg/day for 4 days) and cyclophosphamide (50 mg/kg/day for 4 days). The patient received 4.8 Â 10
8 of non-T-cell depleted nucleated cells/kg. Immunosuppressive treatment included cyclosporine A for 12 months and methylprednisolone given from day 68 to day 143 post-HSCT for cutaneous graft-versus-host disease. Amikacin was administrated until day 36 post BMT while ciprofloxacin was prolonged until day 129 post-HSCT. Low dose of cotrimoxazole (3 mg/kg/day 5/7 days) was given for 12 months. Bone marrow recovery occurred after 20 days for absolute neutrophil count 41000/mm 3 . Full engraftment with 97.5% donor chimerism based on cytogenetic analysis was observed 2 months after transplantation and remained stable since then. Plasma level of IFN-g was normalized (0 pg/ml) on day 26 post-HSCT and remained at this level ever since. Likewise, in vitro stimulation of whole blood with BCG plus IFN-g indicates restoration of a healthy phenotype with a production of 6 and 35 pg/ml of IL-12p70 detected after 48 h of activation at month 6 and 12 post-HSCT, respectively. 8 Two years after transplantation, the patient is currently in good condition with no sign of mycobacterial infection.
A recent study has described the clinical features of patients with IFNgR1 deficiency.
3 Consistently with our observation, patients with recessive complete IFNgR1 deficiency are younger, are infected with less pathogenic fast-growing mycobacteria and have more severe and disseminated infections than those with dominant partial deficiency. Several patients with dominant partial IFNgR1 deficiency have been reported with mycobacterial osteomyelitis initially misdiagnosed as Langerhans cell histio-cytosis (LCH). 10 Our patient is the first case of recessive complete IFNgR1 deficiency who presents with a condition mimicking LCH. Whether the child had some residual IFNgR1 function that could not be detected in vitro or whether the appearance of LCH is heterogeneous and occurs in both complete and partial defects, remains to be determined. Our patient developed skin and lymph nodes rather than lytic bone lesions. We detected the presence of CD1a-bearing cells suggesting that despite expression of both S100 and CD1a, an absence of Birbeck granules, a consanguinity history and/or an unexplained positive Mantoux skin test should lead to investigation in order to exclude occult mycobacterial infection in the context of complete or partial IFNgR1 deficiency.
Patients with complete IFNgR1 deficiency have a poor prognosis with only 4/22 survivors (18%). 6 One-third of them die from their first recognized mycobacterial infection while others have chronic disease that does not resolve on treatment or relapsed rapidly after discontinuation of antibiotics. 3 In addition to our patient, 11 HSCTs in 8 patients with complete IFNgR1 deficiency have been reported. 6 Four patients died shortly after HSCT, two survivors had very low engraftment and only two patients were in full remission of mycobacterial disease 5 years after HSCT from HLA-identical sibling. Two patients had evidence of M. avium complex (MAC) in the blood or in the bone marrow when treated by HSCT. Both patients died from their infection. In our patient, fast growing M. fortuitum was initially found in lymph node biopsy but was no longer detected after initiating antibiotherapy. Thus, although antibiotics were not able to eradicate infection, they probably decreased mycobacterial load. We performed HSCT after 6 months of optimal antibiotic treatment when clinical and biological signs of active infection reappeared in our patient. The absence of infectious complication suggests that rapid engraftment, targeted antibiotherapy and reduced mycobacterial load were sufficient to control infection in our patient. Nevertheless, this encouraging result does not necessarily imply that early HSCT in patients infected with more pathogenic MAC is likely to be as successful than in our patient.
In summary, while we acknowledge that infection control before HSCT is recommended, this report demonstrates that HSCT can be successfully achieved in the presence of active mycobacterial infection in patients with complete IFNgR1 deficiency. Department of Pediatric Hematology-Oncology, St-Luc University Hospital, Catholic University of Louvain, Brussels, Belgium;
